Is Washington Building a Blueprint for MFN Through Trade Policy?

Something interesting is happening in pharmaceutical policy, and executives should be paying attention.

We are hearing growing calls for Washington to pursue an agreement with Germany similar to the U.S.–UK pharmaceutical arrangement as part of the ongoing Section 301 investigation into German drug pricing.

At first glance, this looks like another trade dispute. The bigger question is whether we are beginning to see a potential blueprint for pursuing the goals behind Most Favored Nation drug pricing.

What is happening?

In June, the U.S. Trade Representative opened a Section 301 investigation into Germany's pharmaceutical pricing and reimbursement practices. USTR wants to determine whether what it calls Germany's “persistent underpayment” for innovative medicines is unreasonable or discriminatory and burdens U.S. commerce.

That is unusual because Section 301 is a trade enforcement tool. Germany's drug reimbursement system, on the other hand, is part of its domestic healthcare system.

The U.S. is essentially asking whether decisions made inside another country's healthcare system can create an unfair burden on American commerce.

Now comes the interesting part. Rather than simply looking toward trade retaliation, there are growing calls for a negotiated solution similar to the one reached with the UK.

The UK may have shown us the model

The U.S.–UK agreement connected pharmaceutical pricing directly with trade.

The UK agreed to increase the net price paid by the NHS for prospective new medicines by 25 percent, increase spending on new medicines over time and limit certain pharmaceutical repayment rates. In return, the United States provided significant protections from pharmaceutical tariffs.

Importantly, the agreement itself connects those commitments to U.S. Most Favored Nation policies.

That makes what is happening with Germany worth watching.

In July, I discussed this possibility with Melanie Whittington at the Leerink Center for Pharmacoeconomics. We talked about whether the U.S.–UK arrangement could become a template for Germany.

My view was that it could be a political template, but Germany would be a harder test. Germany has a different statutory reimbursement system, operates through AMNOG and sits within the European Union.

We may now be seeing that test begin.

Where does MFN fit?

The basic argument behind MFN is relatively simple.

The United States believes Americans pay too much for medicines while other wealthy countries pay too little, leaving the U.S. market carrying a disproportionate share of the cost of pharmaceutical innovation.

There are two ways to narrow that gap.

Washington can try to bring American prices closer to those paid overseas. Or it can try to move prices overseas closer to those paid in America.

The UK agreement demonstrates that Washington is willing to work on the second side of that equation. The Germany investigation may tell us whether that approach can be repeated.

That does not mean Section 301 is MFN. Nor has USTR announced that trade enforcement is the mechanism through which MFN will be implemented.

But it raises an important possibility: trade policy may become one of the tools Washington uses to pursue the broader economic objective behind MFN.

Why should executives care?

If you run a pharmaceutical or biotech company, this changes the way international pricing risk should be viewed.

Germany is still Germany. The UK is still the UK. France, Italy, Spain and other markets continue to have their own reimbursement systems, budget pressures and approaches to determining value.

Those decisions may no longer remain entirely within those national systems.

U.S. trade policy could become another factor.

That has potential implications for launch sequencing, market access, reference pricing, revenue assumptions and investment decisions. A decision that once looked like a German reimbursement issue could eventually have consequences for a company's broader global strategy.

If Germany ultimately reaches an arrangement resembling the UK deal, the obvious question will be what country comes next.

The bigger signal

This is the type of development we look at closely at Lanton Strategies International.

Not because every Section 301 investigation will change pharmaceutical markets, but because understanding what is happening often requires looking across policy silos.

MFN looks like U.S. drug pricing policy. AMNOG looks like German reimbursement policy. Section 301 looks like trade policy. The U.S.–UK agreement looks like a bilateral trade arrangement.

The important part is the connection between them. What happens in reimbursement is beginning to influence trade policy, and trade policy may, in turn, influence how countries approach drug pricing.

We do not yet know whether Germany will result in another UK-style agreement. But if it does, pharmaceutical executives may need to reconsider how they think about global pricing risk.

The bigger question we have to consider is how Washington brings prices overseas closer to those paid in the United States.

Independent analysis from Lanton Strategies International. This article does not constitute legal advice.

Generic Drug Tariffs Are Not Yet Policy. Companies Still Need a Plan

President Trump has announced that imported generic drugs would remain subject to a zero tariff for two years beginning August 1, 2026. The tariff would then rise to 100% for one year and 200% thereafter. The stated objective is to encourage more pharmaceutical manufacturing in the United States.

The announcement has generated immediate concern about drug prices, shortages, and the exposure of manufacturers that rely heavily on production outside the United States.

There is an important distinction, however, between a policy announcement and an enforceable tariff.

As of July 23, 2026, no new executive order, presidential proclamation, Federal Register notice, Customs and Border Protection guidance, or amendment to the Harmonized Tariff Schedule has been issued to implement the announced generic-drug tariffs.

The existing legal position still says the opposite. The pharmaceutical tariff proclamation issued in April expressly provides that generic pharmaceuticals, biosimilars, and their associated ingredients are not subject to Section 232 tariffs “at this time.” It directs the Secretary of Commerce to continue monitoring generic imports and report within one year on whether additional action may be appropriate.

The announced tariff schedule should therefore be treated as a serious business signal, not as an operative legal obligation.

The Details Will Determine the Real Exposure

Any implementing action would need to answer questions that could materially change its commercial effect.

Would the tariffs apply only to finished generic drugs, or also to active pharmaceutical ingredients and key starting materials? Would biosimilars remain within the generic category? How would the government determine a product’s country of origin when different manufacturing stages occur in different jurisdictions?

It is also unclear whether manufacturers could qualify for lower rates by building or expanding U.S. production. The existing branded-pharmaceutical tariff framework provides different treatment for certain companies with approved onshoring plans, pricing agreements, or operations in countries covered by trade arrangements. Companies should not assume that the same structure will automatically be extended to generics.

Until those details are established, manufacturers cannot calculate their potential tariff liability. Distributors, pharmacies, health plans, and healthcare providers also cannot determine how additional costs might move through the supply chain.

Generic-Drug Economics Make the Risk Different

Generic drugs frequently operate under narrow margins, competitive purchasing contracts, and reimbursement structures that may not adjust quickly when acquisition costs rise.

A manufacturer may not be able to absorb a substantial tariff. It may also lack the contractual ability to pass the full cost to a wholesaler or customer.

For some products, the response may not simply be a higher price. Manufacturers could reconsider whether it remains economically viable to continue supplying a particular drug to the U.S. market.

That creates a potential availability risk, especially for low-margin products, drugs with few suppliers, and medicines already vulnerable to shortage.

Reshoring could strengthen pharmaceutical supply chains over time. Tariffs alone, however, do not resolve the capital, workforce, regulatory, contracting, reimbursement, and purchasing challenges that determine whether domestic generic manufacturing is commercially sustainable.

What Companies Should Do Now

Companies should not treat the announced rates as settled policy or make definitive customs conclusions before formal implementation documents are issued. They should, however, begin evaluating their potential exposure now.

Generic manufacturers and importers can begin mapping products by manufacturing location, ingredient source, country of origin, margin, tariff classification, and contractual ability to pass through higher costs.

Distributors, pharmacies, health plans, and health systems should identify products for which a tariff could create the greatest cost or availability risk.

Investors should evaluate which companies possess credible domestic manufacturing options and which remain dependent on policy exemptions or continued access to lower-cost foreign production.

Leaders should also model several possible outcomes, including:

• Continued exemption for generic drugs

• Tariffs limited to selected products, ingredients, or countries

• Reduced rates for companies making approved U.S. manufacturing commitments

• Broader tariffs covering both finished products and pharmaceutical ingredients

Each scenario could produce different decisions involving sourcing, inventory, contracts, capital investment, pricing, and continued participation in the U.S. market.

The tariff is not yet policy. The strategic question is whether companies will understand their exposure before it becomes one.

Lanton Strategies International advises healthcare, life-sciences, and investment organizations on how trade policy, regulation, reimbursement, market access, and capital developments affect business strategy and commercial execution across the United States, European Union, and United Kingdom.

When Drug Pricing Becomes a Trade Dispute

The United States has launched a Section 301 investigation into Germany over pharmaceutical pricing and reimbursement policies, with USTR characterizing the issue as “persistent underpayment for innovative pharmaceutical products.”

For multinational pharmaceutical and biotech companies operating across the Atlantic corridor, this is an important regulatory and market access signal.

The investigation appears tied to German healthcare cost-containment legislation that could further reduce spending on innovative medicines. While the trade process may take time to unfold, the larger issue is already clear: domestic healthcare pricing policy is now being viewed through a trade enforcement lens.

That matters because Germany is not just another European market. It is one of the most important pharmaceutical markets in Europe, and its reimbursement policies can influence launch sequencing, pricing strategy, and broader European market planning.

For life sciences companies, this creates a new layer of uncertainty. Pricing, reimbursement, intellectual property protection, market access, and trade enforcement are no longer separate conversations. They are becoming part of the same commercial risk analysis.

The investigation also reflects a broader U.S. policy argument: American patients and companies should not carry a disproportionate share of the global cost of pharmaceutical research and development while other wealthy markets use aggressive reimbursement controls to limit spending.

This does not mean tariffs are inevitable. USTR has suggested that the issue could potentially be resolved through negotiations, including a path that expands access to innovative medicines while ensuring fair reimbursement for pharmaceuticals made by American workers. Still, the use of Section 301 against Germany is significant because it shows how quickly pricing policy can become a trade dispute.

For pharmaceutical and biotech companies, the takeaway is clear. Market-entry strategy cannot focus only on regulatory approval or clinical value. It also has to account for how governments use pricing rules, budget controls, and trade tools to shape the value of innovation.

This is exactly the type of geopolitical and market access risk we track closely at Lanton Strategies International. As pricing policy and international trade enforcement continue to intersect, companies will need to think more carefully about where they launch, how they price, and how policy risk affects long-term commercial planning.

The United Kingdom Is Beginning to Align with U.S. Drug Pricing Pressure

The recent pharmaceutical arrangement between the United States and the United Kingdom is not simply a trade development. It is an early indication of how sustained U.S. pricing pressure is beginning to influence decision-making in other markets.

The structure of the agreement is straightforward. The United Kingdom secures tariff-free access to the U.S. market. In return, it accepts higher net prices for innovative medicines and commits to increased pharmaceutical spending over time. That exchange reflects a broader shift. Trade access is now being linked more directly to pricing outcomes.

This is not an isolated development. It is part of a policy environment where pricing, trade, and industrial strategy are increasingly connected. Tariffs are no longer being used solely as protective measures. They are being positioned as leverage to influence how and where value is recognized across markets.

The United Kingdom’s response is notable because it is proactive. It does not reflect a market waiting to see whether U.S. policy will persist. It reflects a market beginning to plan around that persistence. That distinction has strategic implications.

For pharmaceutical companies operating across the United States and Europe, the planning environment is changing. Pricing strategy can no longer be developed independently of trade exposure. Launch sequencing is becoming more sensitive to cross-border dynamics. Manufacturing decisions are increasingly tied to both market access and policy risk.

The implication is not that a single agreement will reshape the market. It is that this type of alignment may become more common. As that occurs, companies will need to assess how policy signals in one jurisdiction influence positioning in another.

This is not a dynamic that can be deferred. It is one that requires active coordination across pricing, market access, and corporate strategy.